Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have been given an average rating of “Buy” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $20.00.
Several analysts recently commented on the stock. Oppenheimer raised their price objective on shares of Capricor Therapeutics from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday.
Get Our Latest Report on Capricor Therapeutics
Hedge Funds Weigh In On Capricor Therapeutics
Capricor Therapeutics Price Performance
Capricor Therapeutics stock opened at $4.99 on Tuesday. The business has a 50 day simple moving average of $4.36 and a 200-day simple moving average of $5.18. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28. The stock has a market capitalization of $159.58 million, a PE ratio of -5.74 and a beta of 3.92.
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities research analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current year.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
- Five stocks we like better than Capricor Therapeutics
- The Basics of Support and Resistance
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What to Know About Investing in Penny Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Invest in Blue Chip Stocks
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.